EGFR and neoplasm: Further, two other bispecific CD16a-based tumor targeting antibodies are in preclinical phase development, i.e., AFM22 and AFM24 that bind to EGFRvIII expressed by several solid tumors, including glioblastoma (GBM), and wild-type EGFR, respectively.